Drug Metabolism

PhysioMimix™ Organ-on-Chip studies can be used to study the metabolism of drugs, gaining insights into the rate of metabolism and the role of metabolites.

Using PhysioMimix™ will enable users to:

Model a human environment generating human specific metabolites
Allows long term cell culture of metabolically active cells
Easily measure drug levels in cells and their environment

The liver is the principal site of drug metabolism and CN-Bio’s Liver-on-Chip system is ideal for these types of studies.

PBPK Modelling

CN Bio’s microphysiological technology is underpinned by deep expertise in physiologically-based pharmacokinetic (PBPK) modelling. This is a mathematical modelling technique for predicting the absorption, distribution and metabolism of drugs and chemicals in humans and animals.

Collaborating With Regulators

CN Bio aims to promote MPS technologies, working with regulators and industry to help them understand how these Organ-on-Chip devices can be used for regulatory submissions.

In 2018 CN Bio signed a multi-year deal with the US Food and Drug Administration (FDA), the world’s most prominent pharmaceutical regulatory agency. This collaboration aims to evaluate the use of CN Bio’s Organs-on-Chips in FDA drug interaction and safety studies.

Human organ
mimics

Powerful new
data

Translatable
results

COMPANY HEAD OFFICE INFORMATION:

CN Bio Innovations Limited
BioPark Hertfordshire
Broadwater Road
Welwyn Garden City
Hertfordshire
AL7 3AX, UK

+44 (0) 1707 358 739
enquiries@cn-bio.com

FOR PRODUCT, SERVICES AND MARKETING ENQUIRIES:

enquiries@cn-bio.com
+44 (0) 1707 358 739

CN BIO INNOVATIONS LIMITED REGISTERED OFFICE:

30 Upper High Street, Thame,
Oxfordshire, OX9 3EZ.

Registered No. 06517359.
VAT No. 978184563